Rapidly Progressive IgA Nephropathy in a Young Male - Stage 3b CKD
Case at a Glance
A 28-year-old Spanish male with a 13-year history of IgA nephropathy presenting with rapidly declining renal function, progressing from eGFR 50 to 39 mL/min/1.73m² over 6 months despite antihypertensive therapy.
Patient's Story
The patient was diagnosed with IgA nephropathy at age 15 and has maintained good self-care throughout his disease course. He reports feeling physically fit and healthy with no impact on daily activities. However, he expresses significant anxiety about potential future need for dialysis and its associated complications including fatigue, weight gain, and sexual dysfunction. He has concerns about how his condition might affect his planned international relocation. The patient has made dietary modifications, nearly eliminating meat consumption, and has reduced his exercise frequency due to fatigue and dyspnea following increased Losartan dosing.
Initial Assessment
Recent laboratory results show eGFR decline from 50 to 41 mL/min/1.73m² over 6 months, with further deterioration to 39 mL/min/1.73m² despite addition of spironolactone. Patient is currently on Losartan (Cozaar) and recently added spironolactone. He has self-initiated curcumin supplementation and inquires about probiotic therapy. Physical examination reveals a slim, apparently healthy-appearing male with no obvious signs of uremia or fluid overload.
The Diagnostic Journey
The patient was diagnosed with IgA nephropathy 13 years prior at age 15. He underwent a trial of prednisone therapy for 6 months in the past, which was discontinued due to significant adverse effects. Current monitoring shows accelerated progression to Stage 3b chronic kidney disease. Patient attributes potential contributing factors to stress and dietary habits, specifically daily consumption of chocolate cereals.
Final Diagnosis
IgA Nephropathy with Stage 3b Chronic Kidney Disease (eGFR 39 mL/min/1.73m²) showing rapid progression
Treatment Plan
Current regimen includes Losartan and spironolactone for blood pressure control and proteinuria reduction. The patient is being evaluated for atrasentan therapy as part of a clinical assessment. Discussion regarding immunosuppressive therapy options beyond corticosteroids is planned, given the patient's previous poor tolerance to prednisone. Dietary counseling and exercise modification recommendations to accommodate current symptoms while maintaining cardiovascular health.
Outcome and Follow-up
Patient scheduled for nephrology follow-up in one month to reassess renal function and discuss potential initiation of atrasentan therapy. Long-term monitoring plan includes regular assessment of eGFR trends, proteinuria levels, and blood pressure control. Patient education provided regarding CKD progression, dialysis preparation timeline, and transplant evaluation criteria. Counseling regarding international healthcare considerations for his planned relocation.